Ptc Therapeutics (PTCT) EPS (Weighted Average and Diluted) (2012 - 2026)
Ptc Therapeutics (PTCT) recorded quarterly EPS (Weighted Average and Diluted) of -$0.03 in Q1 2026, up 98.2% quarter-over-quarter from -$1.67 in Q4 2025, and down 100.3% on a YoY basis from $10.04 in Q1 2025.
Ptc Therapeutics (PTCT) EPS (Weighted Average and Diluted) (2012 - 2026) Analysis & Trends
Ptc Therapeutics' EPS (Weighted Average and Diluted) history runs 11 years deep, the most recent figure standing at -$0.03 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 100.3% year-over-year to -$0.03; the TTM figure through Mar 2026 stood at -$2.33 (down 135.79% YoY), while the FY2025 annual figure was $7.78, up 264.48% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.03 for Q1 2026 at Ptc Therapeutics, up from -$1.67 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $10.04 in Q1 2025 to a low of -$2.66 in Q2 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.78 across 5 years, with a median of -$1.53 in 2022.
- The sharpest annual moves came in 2025 and 2026: EPS (Weighted Average and Diluted) surged 936.67% in 2025, then plunged 100.3% in 2026.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$2.36 in 2022, then grew by 12.71% to -$2.06 in 2023, then surged by 58.74% to -$0.85 in 2024, then sank by 96.47% to -$1.67 in 2025, then jumped by 98.2% to -$0.03 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.03 (Q1 2026), -$1.67 (Q4 2025), and $0.2 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Ptc Therapeutics | 6.51 Bn | 4.61 Bn | 244.52 Mn | -0.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.03 |
| Dec 31, 2025 | -1.67 |
| Sep 30, 2025 | 0.20 |
| Jun 30, 2025 | -0.83 |
| Mar 31, 2025 | 10.04 |
| Dec 31, 2024 | -0.85 |
| Sep 30, 2024 | -1.39 |
| Jun 30, 2024 | -1.29 |
| Mar 31, 2024 | -1.20 |
| Dec 31, 2023 | -2.06 |
| Sep 30, 2023 | -1.76 |
| Jun 30, 2023 | -2.66 |
| Mar 31, 2023 | -1.88 |
| Dec 31, 2022 | -2.36 |
| Sep 30, 2022 | -1.53 |
| Jun 30, 2022 | -2.13 |
| Mar 31, 2022 | -1.78 |
| Dec 31, 2021 | -2.02 |
| Sep 30, 2021 | -1.89 |
| Jun 30, 2021 | -1.68 |